Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Distinct changes in transcriptional profiles and epigenetic patterns mediated by EZH2 inhibitors in sensitive and insensitive prostate cancer cells

ABSTRACT: Distinct changes in transcriptional profiles and epigenetic patterns mediated by EZH2 inhibitors in sensitive and insensitive prostate cancer cells

PROVIDER: PRJNA318379 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR3375960.fastq.gz	Fastqsanger.gz
	SRR3376070.fastq.gz	Fastqsanger.gz
	SRR3376080.fastq.gz	Fastqsanger.gz
	SRR3375961.fastq.gz	Fastqsanger.gz
	SRR3376071.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 21

Similar Datasets

Xrn1-sensitive lncRNAs are insensitive to Dbp2 nuclear depletion

Project description:Xrn1-sensitive lncRNAs are insensitive to Dbp2 nuclear depletion

| PRJNA986458 | ENA

Determining lovastatin-induced differences in expression between statin sensitive and insensitive MM cells

Project description:The goals of this study were to determine global differences in transcript expression and regulation between MM cells that are sensitive or insensitive to lovastatin-induced apoptosis. To this end, two sensitive (KMS11 and H929) and two insensitive (LP1 and SKMM1) MM cell lines treated with 20uM lovastatin or an ethanol vehicle control for 16 hours. mRNA was extracted and prepared for mRNA expression microarrays (HG-U133 Plus 2) in triplicate. Keywords: drug-response across cell-lines

2009-11-24 | GSE15946 | GEO

Determining lovastatin-induced differences in expression between statin sensitive and insensitive MM cells

2010-05-20 | E-GEOD-15946 | biostudies-arrayexpress

EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin Lymphoma [ChIP-seq]

Project description:Pharmacological inhibition of the histone lysine methyltransferase EZH2 has emerged as a therapeutic strategy for the treatment of non-Hodgkin Lymphoma (NHL), in particular for cases with mono-allelic mutations in the EZH2 catalytic domain. Potent, selective EZH2 small molecule inhibitors have achieved tumor regression in mutant EZH2-containing preclinical lymphoma models and several of these inhibitors are currently engaged in cancer-focused clinical trials. Here, we show that the presence of EZH2 mutations do not always confer EZH2 inhibitor sensitivity. We discovered that EZH2 is usurped by lymphoma cells to attenuate JAK/STAT signaling and to repress pro-apoptotic interferon response genes. EZH2 inhibition results in the broad induction of interferon-stimulated genes (ISGs) in several phenotypically sensitive NHL cell models. In mutant EZH2-containing insensitive models, EZH2 inhibitors synergize specifically with type I interferons (IFNs) in vitro and in vivo to induce ISGs and apoptosis. The profound combinatorial activity of EZH2 inhibitors and type I IFNs is not restricted to NHL models with mutant EZH2 and, is preferentially observed in models that are not affected by either single agent. Molecular consequences of EZH2 inhibitor and type I IFN combinatorial treatment include STAT1 activation, binding of STAT transcription factor complexes to ISGs, reduction of H3K27me3 levels and increase of H3K4me3 levels at ISG transcriptional start sites, and ISG transcriptional activation. The molecular and anti-proliferative effects of the combination can be suppressed by inactivation of the JAK/STAT signaling pathway, by using the JAK inhibitor ruxolitinib. We suggest that EZH2 inhibitors can be therapeutically combined with type I IFNs for the treatment of NHL.

2023-01-06 | GSE70702 | GEO

EZH2 suppresses the interferon-stimulated gene response in non-Hodgkin Lymphoma [RNA-seq]

2023-01-06 | GSE70622 | GEO

EZH2 inhibitor-mediated transcriptional profiling in prostate cancer cells [RNA-seq]

Project description:We reported here the gene expression profiles that were mediated upon the treatment of EZH2 inhibitor in two hormone-refractory prostate cancer cell lines: the sensitive, AR-positive abl cells and the insensitive, AR-null DU145 cells.

2017-09-01 | GSE80239 | GEO

RNASeq of cold-sensitive and cold-insensitive neurons from the pre-optic area of hypothalamus of mice

Project description:The preoptic area of the hypothalamus (POA) contains intrinsically warm and cold-sensitive neurons, which are thought to be critically involved in mammalian thermoregulation. However, the precise physiological roles and the molecular markers of the cold-sensitive POA neurons have not been determined yet. Here, we tackle this problem by performing calcium-imaging guided separation and collection of cold-sensitive and cold-insensitive dissociated neurons from the mouse POA, followed by RNASeq and differential transcriptomics of these cell populations.

2020-04-09 | GSE136396 | GEO

Distinct changes in transcriptional profiles and epigenetic patterns mediated by EZH2 inhibitors in sensitive and insensitive prostate cancer cells

Project description:This SuperSeries is composed of the SubSeries listed below.

2017-09-01 | GSE80240 | GEO

Catalytic subunits switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells [RNA-seq]

Project description:The SWI/SNF chromatin remodeling complex is altered in ~20% of human cancers. ARID1A, a component of the SWI/SNF chromatin-remodeling complex, is the most frequently mutated epigenetic regulator in human cancers. Inactivation of the SWI/SNF complex is synthetically lethal with inhibition of EZH2 activity. EZH2 inhibitors are entering clinical trials for specific tumor types with SWI/SNF mutations. However, mechanisms of de novo or acquired resistance to EZH2 inhibitors in cancers with inactivating SWI/SNF mutations are unknown. Here we show that the switch of the SWI/SNF catalytic subunits from SMARCA4 to SMARCA2 drives resistance to EZH2 inhibitors in ARID1A-mutated ovarian cancer cells.

2019-02-10 | GSE110449 | GEO

Catalytic subunits switch drives resistance to EZH2 inhibitors in ARID1A-mutated cells [ChIP-seq]

2019-02-10 | GSE110448 | GEO